ホーム › 急性二系統白血病 › カリフォルニア州

カリフォルニア州における急性二系統白血病の臨床試験

カリフォルニア州内の拠点で、急性二系統白血病に関する15件の研究が参加者を募集しています。

カリフォルニア州内の都市

公式研究テキスト（英語）

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

City of Hope, Duarte
UC Davis, Sacramento
Stanford Health Care, Stanford

被験者募集中第1相

12歳〜78歳 · 全性別 · 2026/09/29更新 · NCT03802695

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Loma Linda University Medical Center, Loma Linda
Miller Children's and Women's Hospital Long Beach, Long Beach
UCSF Benioff Children's Hospital Oakland, Oakland
他4件

被験者募集中第2相

365 Days · 全性別 · 2026/09/25更新 · NCT06317662

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Kaiser Permanente Downey Medical Center, Downey
City of Hope Comprehensive Cancer Center, Duarte
Loma Linda University Medical Center, Loma Linda
他14件

被験者募集中第3相

365 Days – 25 Years · 全性別 · 2026/08/25更新 · NCT03959085

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Kaiser Permanente Downey Medical Center, Downey
Loma Linda University Medical Center, Loma Linda
Miller Children's and Women's Hospital Long Beach, Long Beach
他8件

被験者募集中第1/2相

22歳以下 · 全性別 · 2026/08/25更新 · NCT04726241

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

Rady Children's Hospital, San Diego

被験者募集中第2相

1歳〜18歳 · 全性別 · 2026/08/10更新 · NCT06390319

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

City of Hope, Duarte
Valkyrie Clinical Trials, Los Angeles

被験者募集中第1/2相

13歳〜90歳 · 全性別 · 2026/08/06更新 · NCT06533579

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Rady Children's Hospital, San Diego

被験者募集中第1相

1歳〜30歳 · 全性別 · 2026/08/03更新 · NCT06177067

Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

Rady Children's Hospital, San Diego

被験者募集中第4相

1歳〜18歳 · 全性別 · 2026/07/14更新 · NCT06289673

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

UCLA Department of Medicine, Los Angeles

被験者募集中第2相

18歳以上 · 全性別 · 2026/07/07更新 · NCT07216443

Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT

Stanford University, Palo Alto

被験者募集中第1相

18歳〜70歳 · 全性別 · 2026/06/23更新 · NCT06551584

A Study of Revumenib and Mezigdomide in People With Leukemia

City of Hope Cancer Center (Data collection only), Duarte

被験者募集中第1/2相

12歳以上 · 全性別 · 2026/06/22更新 · NCT07356154

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

City of Hope, Duarte
Los Angeles Cancer Network, Los Angeles
UCLA Medical Center of Hematology/Oncology, Los Angeles
他1件

被験者募集中第1/2相

12歳〜95歳 · 全性別 · 2026/04/15更新 · NCT04329728

Venetoclax Basket Trial for High Risk Hematologic Malignancies

University of California San Francisco-Benioff Children's Hospital, San Francisco

被験者募集中第1相

1歳〜40歳 · 全性別 · 2026/03/12更新 · NCT05292664

Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant

City of Hope Medical Center, Duarte

被験者募集中第1相

2歳以上 · 全性別 · 2026/03/05更新 · NCT06575296

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Children's Hospital Los Angeles, Los Angeles
Children's Hospital Orange County, Orange
UCSF School of Medicine, San Francisco

被験者募集中第1相

1歳〜21歳 · 全性別 · 2024/12/06更新 · NCT05476770

ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。